RedHill Biopharma Ltd. (RDHL)
RDHL Stock Price Chart
Explore RedHill Biopharma Ltd. interactive price chart. Choose custom timeframes to analyze RDHL price movements and trends.
RDHL Company Profile
Discover essential business fundamentals and corporate details for RedHill Biopharma Ltd. (RDHL) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
7 Jan 2013
Employees
35.00
Website
https://www.redhillbio.comCEO
Dror Ben-Asher
Description
RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioid-induced constipation in adults experiencing chronic non-cancer pain; Talicia, used to treat Helicobacter pylori infections in adult patients; and Aemcolo, prescribed for adults suffering from travelers' diarrhea. Its robust late-stage clinical pipeline features several promising investigational compounds. RHB-204 is currently in Phase 3 for pulmonary nontuberculous mycobacteria infections. Opaganib (Yeliva), an SK2 selective inhibitor, has completed Phase 2 for severe SARS-CoV-2 related COVID-19 pneumonia, is in Phase 2 for advanced unresectable cholangiocarcinoma, and is also being investigated in a researcher-sponsored Phase 2 study for prostate cancer. RHB-107 is progressing through Phase 2/3 trials for COVID-19 outpatients, is undergoing preclinical evaluation for advanced unresectable cholangiocarcinoma, and has successfully concluded Phase 2 studies for gastrointestinal and other solid tumors. Furthermore, RHB-104 is in Phase 3 development for Crohn's disease. RHB-102 (Bekinda) is also in Phase 3 for acute gastroenteritis and gastritis, following its successful completion of Phase 2 for irritable bowel syndrome with diarrhea. Lastly, RHB-106, an encapsulated formulation designed for bowel preparation, is preparing to commence Phase 2/3 clinical studies. Established in 2009, RedHill Biopharma Ltd. maintains its headquarters in Tel Aviv, Israel.
RDHL Financial Timeline
Browse a chronological timeline of RedHill Biopharma Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 20 Aug 2026
EPS estimate is -$435.00, while revenue estimate is $22.70m.
Earnings released on 30 Mar 2026
Earnings released on 12 Mar 2026
Earnings released on 5 Sept 2025
EPS came in at -$1.00 surpassing the estimated -$690.00 by +99.86%, while revenue for the quarter reached $2.04m , missing expectations by -53.42%.
Earnings released on 10 Apr 2025
EPS came in at -$1.00 surpassing the estimated -$690.00 by +99.86%, while revenue for the quarter reached $2.04m , missing expectations by -53.42%.
Earnings released on 3 Oct 2024
EPS came in at $9.00 surpassing the estimated -$3.68 by +344.57%, while revenue for the quarter reached $2.74m , missing expectations by -1.05%.
Stock split effective on 20 Aug 2024
Shares were split 1 : 25 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 30 Jul 2024
EPS came in at -$2.00 falling short of the estimated -$0.30 by -566.67%, while revenue for the quarter reached $1.29m , missing expectations by -95.00%.
Earnings released on 8 Apr 2024
EPS came in at -$1.00 , while revenue for the quarter reached $1.29m , missing expectations by -95.00%.
Earnings released on 14 Mar 2024
EPS came in at -$0.20 falling short of the estimated -$0.03 by -566.67%, while revenue for the quarter reached $567.50k , missing expectations by -97.79%.
Earnings released on 6 Nov 2023
EPS came in at -$24.00 falling short of the estimated $1.39 by -1.83k%, while revenue for the quarter reached $567.50k , missing expectations by -97.65%.
Earnings released on 30 Jun 2023
EPS came in at $4.83 surpassing the estimated $1.19 by +305.88%, while revenue for the quarter reached $1.80m , missing expectations by -15.00%.
Earnings released on 12 Jun 2023
EPS came in at $1.47 surpassing the estimated $0.01 by +10.16k%, while revenue for the quarter reached $3.60m , missing expectations by -0.58%.
Earnings released on 28 Apr 2023
EPS came in at -$1.00 surpassing the estimated -$690.00 by +99.86%, while revenue for the quarter reached $12.80m , missing expectations by -29.28%.
Stock split effective on 23 Mar 2023
Shares were split 1 : 40 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 15 Mar 2023
EPS came in at -$0.50 falling short of the estimated $1.95 by -125.64%, while revenue for the quarter reached $12.80m , missing expectations by -27.09%.
Earnings released on 7 Nov 2022
EPS came in at -$2.00 falling short of the estimated -$0.30 by -566.67%, while revenue for the quarter reached $17.55m , missing expectations by -18.37%.
Earnings released on 23 Sept 2022
EPS came in at -$1.03 falling short of the estimated -$0.10 by -930.00%, while revenue for the quarter reached $18.35m , missing expectations by -14.67%.
Earnings released on 23 Jun 2022
EPS came in at -$3.00 surpassing the estimated -$4.00 by +25.00%, while revenue for the quarter reached $18.24m , missing expectations by -22.73%.
Earnings released on 17 Mar 2022
EPS came in at -$5.00 falling short of the estimated -$4.00 by -25.00%, while revenue for the quarter reached $22.07m , missing expectations by -8.37%.
Earnings released on 30 Nov 2021
EPS came in at -$4.60 surpassing the estimated -$4.80 by +4.17%, while revenue for the quarter reached $21.61m , missing expectations by -11.87%.
Earnings released on 26 Aug 2021
EPS came in at -$6.20 falling short of the estimated -$4.00 by -55.00%, while revenue for the quarter reached $21.50m , missing expectations by -20.36%.
RDHL Stock Performance
Access detailed RDHL performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
